Clifford Chance advises Pfizer and Freshfields advises the independent board of Haleon on the demerger of Haleon from GSK and its dual listing in London and New York.
Haleon plc acted as the acquirer in this Demerger transaction.
The acquisition targeted assets operating in the Consumer Healthcare sector.
The transaction was announced on 15 Jun 2022 with a reported value of 364000000000.0.
Generated by AI, original source from - Data is in progress
GSK plc advisor
Firm name is in progress
Found it useful? Spread the word.
Clifford Chance advises Pfizer and Freshfields advises the independent board of Haleon on the demerger of Haleon from GSK and its dual listing in London and New York. | The Sponsor - The Sponsor
